{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-000889","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.812285+00:00","generated_at":"2026-05-24T14:47:01.078457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Silexion Therapeutics reports FY2024 results: net loss $16.5M, cash $1.2M, and progress on SIL204","bullets":["Net loss for 2024 was $16.5 million, compared to $5.1 million in 2023.","Cash and cash equivalents as of December 31, 2024 were $1.2 million, down from $4.6 million.","SIL204 showed significant reduction in primary tumor and metastasis in orthotopic pancreatic cancer models.","Company raised approximately $9.1 million in gross proceeds from financings in early 2025.","LODER Phase 2 trial achieved 56% objective response rate in patients with KRAS G12D/V mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-000889","json":"https://secwatch.observer/filing/0001178913-25-000889.json","markdown":"https://secwatch.observer/filing/0001178913-25-000889.md","text":"https://secwatch.observer/filing/0001178913-25-000889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/0001178913-25-000889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/zk2532884.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T14:47:01.078457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}